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Introduction: Endometrial carcinoma is the fourth most common malignancy among women 
and most common gynaecologic malignancy in the developed countries. Its incidence in the 
developing countries is also increasing. The clinical management of patients with endometrial 
cancer depends on various pathological parameters like stage of the tumour, grade of the 
tumour, presence of lymphovascular invasion, lymph node status and histological subtype of 
endometrial carcinomas. Therefore, in addition to the morphology of endometrial carcinoma, 
there is a need for accurate immunohistochemical markers to predict the outcome of the 
disease. But many of these immunohistochemical markers are not feasible to use in routine 
clinical practice due to various reasons. Among the proposed markers for endometrial 
carcinoma, Estrogen Receptor (ER) and Progesterone Receptor (PR) are widely accepted in 
clinical practice. With this background, the present study is performed to assess the 
immunohistochemical expression of ER and PR in endometrial cancers and its precursors.  
Aim: To assess the expression of ER and PR in endometrial carcinomas and its precursors by 
immunohistochemistry. 
 
Materials and Methods: A total of 113 cases(21 cases of disordered proliferation, 29 cases of 
typical hyperplasia,  25 cases of atypical hyperplasia, 20 cases of endometrioid carcinoma, 4 
cases of serous carcinoma and 14 cases of carcinosarcoma, diagnosed from January 2014-
December 2016 were analysed. Immunostaining for ER and PR was performed on these cases 
and was graded for intensity and percentage of positive tumour cells. The ER and PR 
expression was then correlated with the clinical and pathological features of endometrial 
precursors and carcinoma. 
Results: The mean age of preneoplastic lesions of endometrium and carcinoma were 50 and 
58 years respectively. Nulliparity was associated with relatively increased risk of carcinoma. 
Carcinomas were associated with mean endometrial thickness of >5mm. ER and PR 
expression decreased as the grade of the tumour increases. PR expression decreased as the 
stage of the tumour increases. There was no significant difference in ER expression with 
increasing stage of tumour.  
Conclusion: There was no significant difference in the expression of ER and PR in the 
preneoplastic lesions. Strong expression of ER and PR was seen in well and moderately 
differentiated endometrioid carcinoma compared to poorly differentiated endometrioid 
carcinomas, which were mostly negative.  The difference in the immunohistochemical 
expression of ER and PR in endometrioid and serous carcinoma support the different 
pathogenesis of their development. 
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